Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Weight Loss 1Triple Negative Breast Neoplasms 1Thrombocytopenia 1Splenomegaly 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphocytosis 1Lymphadenopathy 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioma 1Fever 1Fatigue 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Anemia 1Advanced Breast Cancer 1

Interventions

Docetaxel 43enzalutamide 31Prednisone 25Abiraterone Acetate 24Magnetic Resonance Spectroscopy 18abiraterone 15pembrolizumab 14bicalutamide 14Radiotherapy 14Cyclophosphamide 13darolutamide 12Leuprolide 12Goserelin 12apalutamide 10Ipilimumab 10olaparib 9Specimen Handling 9Radiosurgery 9Radiation 9Injections 9Biopsy 9Pluvicto 8Paclitaxel 8Radiotherapy, Intensity-Modulated 7Carboplatin 7sargramostim 6fludarabine 6cabazitaxel 6Sirolimus 6Nivolumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Prostatic Neoplasms × Ritonavir × Clear all
NCT05679388 2024-09-19

A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients

University of Chicago

Phase 1 Terminated
60 enrolled
Genitourinary

Prostatic Neoplasms

NCT03066154 2024-06-03

DOP

The Netherlands Cancer Institute

Phase 1 Terminated
24 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡